Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Xenon Pharmaceuticals Inc (NQ: XENE )

38.96 +0.31 (+0.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 349,631
Open 38.74
Bid (Size) 35.75 (1)
Ask (Size) 38.96 (1)
Prev. Close 38.65
Today's Range 38.08 - 39.08
52wk Range 25.92 - 43.57
Shares Outstanding 63,562,303
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xenon Pharmaceuticals to Present at the 2023 Jefferies Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2023 RBC Capital Markets Global Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire

Performance

YTD
+4.56%
+4.56%
1 Month
-3.04%
-3.04%
3 Month
+4.25%
+4.25%
6 Month
+5.50%
+5.50%
1 Year
+46.03%
+46.03%

More News

Read More
Xenon Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Xenon Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Where Xenon Pharmaceuticals Stands With Analysts
Via Benzinga
Earnings Scheduled For March 1, 2023
Via Benzinga
Xenon Pharmaceuticals Earnings Preview
Via Benzinga
The Latest Analyst Ratings for Xenon Pharmaceuticals
Via Benzinga
Xenon Pharmaceuticals Inc. (NASDAQ: XENE) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
Earnings Scheduled For May 9, 2023
Via Benzinga
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2023
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Unlocking Xenon Pharmaceuticals $1B Potential: Analyst Cites Anti-Epileptic Candidate's Untapped Value
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Tuesday, April 25, 2023: GM, SNAP, WEN, XENE, CXAI
Via Benzinga
Xenon Pharmaceuticals Showcases Its XEN1101 Epilepsy Program at the 2023 American Academy of Neurology (AAN) Annual Meeting
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the Stifel 2023 CNS Days
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Xenon Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
Via Investor's Business Daily
Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Following A Merger That Could Help Shape The Industry – A Brief Look At The Company
Via Benzinga
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2023
From Xenon Pharmaceuticals Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.